Viralytics expands patent coverage

Company News

Viralytics Limited (ASX:VLA) has expanded its patent coverage in the US.
 
The biotech company’s lead product CAVATAK is already protected with a portfolio of patents in major world markets.
 
The additional patent allows for broader protection across all Coxsackie A viruses and group C human enteroviruses which play a role in targeting and destroying cancer cells.
 
The news comes days after Viralytics announced plans to raise $27 million to help develop its anti-cancer drug Cavatak by issuing new shares.
 
The funding will enable Viralytics to complete phase two of trials of the drug Cavatak on late-stage melanoma patients.
 
Viralytics booked a net loss of $4.1 million in fiscal 2013.

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?